SEGMENT AND ENTERPRISE-WIDE INFORMATION

12 Months Ended

Mar. 28, 2020

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, the Company's operating segments were based primarily on geography. Effective as of March 31, 2019, the Company completed the transition of its operating structure to three global business units and accordingly, reorganized its reporting structure to align with its three global business units and the information that will be regularly reviewed by the Company's chief operating decision maker.

Following the reorganization, the Company's reportable segments are as follows:


•	Plasma


•	Blood Center


•	Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, accelerated depreciation, costs related to compliance with the European Union Medical Device Regulation, gains and losses on asset dispositions, certain transaction costs and legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:



(In thousands)	2020			2019			2018
Net revenues
Plasma	$	460,637		$	426,781		$	363,254
Blood Center	325,661			335,557			347,373
Hospital	194,604			190,821			178,116
Net revenues by business unit	980,902			953,159			888,743
Service ⁽¹⁾	19,830			19,906			20,574
Effect of exchange rates	(12,253		)	(5,486		)	(5,394		)
Net revenues	$	988,479		$	967,579		$	903,923
⁽¹⁾ Reflects revenue for service, maintenance and parts.



(In thousands)	2020			2019			2018
Segment operating income
Plasma	$	225,351		$	180,300		$	146,986
Blood Center	159,802			163,628			170,172
Hospital	80,669			76,338			67,258
Segment operating income	465,822			420,266			384,416
Corporate expenses ⁽¹⁾	(255,727		)	(263,603		)	(257,229		)
Effect of exchange rates	7,920			8,367			4,060
Impairment of assets and other related charges ⁽²⁾	(51,220		)	(21,170		)	(1,941		)
Deal amortization	(25,746		)	(24,803		)	(26,013		)
PCS2 accelerated depreciation and related costs	(24,530		)	(19,126		)	—
Restructuring and turnaround costs	(19,878		)	(13,660		)	(44,125		)
European Medical Device Regulation costs	(1,506		)	—			—
Other ⁽³⁾	133			(2,726		)	(3,011		)
Gain on sale of assets ⁽⁴⁾	8,083			—			—
Operating income	$	103,351		$	83,545		$	56,157
⁽¹⁾ Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions. ⁽²⁾ Includes a $1.9 million adjustment to fiscal 2020 Plasma revenue due to an accelerated charge incurred as a result of the divestiture of the Union, South Carolina liquid solutions operation. ⁽³⁾ Includes transaction costs and costs related to the resolution of customer damages associated with product recalls. ⁽⁴⁾ Reflects gain on the sale of the Company's Braintree corporate headquarters.



(In thousands)	2020		2019		2018
Depreciation and amortization
Plasma	$	38,429	$	38,074	$	47,985
Blood Center	8,513		9,623		11,439
Hospital	63,347		61,721		29,823
Total depreciation and amortization (excluding impairment charges)	$	110,289	$	109,418	$	89,247



(In thousands)	March 28, 2020		March 30, 2019		March 31, 2018
Long-lived assets⁽¹⁾
Plasma	$	141,903	$	192,628	$	186,007
Blood Center	93,758		127,272		122,898
Hospital	17,738		24,079		23,251
Total long-lived assets	$	253,399	$	343,979	$	332,156
⁽¹⁾ Long-lived assets are comprised of property, plant and equipment.

Selected information by principle operating regions is presented below:



(In thousands)	March 28, 2020		March 30, 2019		March 31, 2018
Long-lived assets⁽¹⁾
United States	$	186,488	$	269,849	$	236,603
Japan	2,037		1,726		1,511
Europe	10,143		11,200		13,696
Asia	29,175		30,930		36,431
Other	25,556		30,274		43,915
Total long-lived assets	$	253,399	$	343,979	$	332,156
⁽¹⁾ Long-lived assets are comprised of property, plant and equipment.



(In thousands)	2020		2019		2018
United States	$	646,204	$	606,845	$	548,731
Japan	72,218		69,908		67,319
Europe	153,347		164,504		164,226
Asia	109,295		118,700		115,127
Other	7,415		7,622		8,520
Net revenues	$	988,479	$	967,579	$	903,923

Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:



(In thousands)	2020		2019		2018
Plasma products and services	537,231		501,837		435,956
Blood Center products and services	252,829		269,203		284,902
Hospital products and services	198,419		196,539		183,065
Net revenues	$	988,479	$	967,579	$	903,923